Award details

Bioprocessing of genetically engineered filamentous phages to underpin new therapeutic and industrial applications

Reference	BB/D521465/1
Principal Investigator / Supervisor	Professor John Ward
Co-Investigators / Co-Supervisors	Professor Eli Keshavarz -Moore
Institution	University College London
Department	Biochemical Engineering
Funding type	Research
Value (£)	242,796
Status	Completed
Type	Research Grant
Start date	01/03/2006
End date	28/02/2009
Duration	36 months

Abstract

Genetically modified filamentous phages, used as epitope display and gene delivery vectors, are showing promise in the battle to defeat diseases such as AIDS and cancer. Entire active enzymes can be expressed on the surface of filamentous phages and this has allowed their use in the directed evolution of enzymes for biocatalysis and could potentially allow enzymes-on-phage to be a biological enzyme immobilisation tool. The highly asymmetric shape of filamentous phage and the ability to express binding domains on the surface has allowed them to be used as ordered semiconducting nanowires on the surface of chips. Modified phages can be produced in high titres from bacteria and in principle processed by techniques readily applicable to considerable scale-up. Until a recent resurgence of interest in phages as anti-microbial agents there has been little research concerned with large-scale phage processing since a few early studies 30 years ago. As the crisis in antibiotic drug resistance by microorganisms continues to develop it is also possible that phages will have an increasing use as topical antibiotics. For this reason modern biochemical engineering and molecular biology concepts have yet to be brought together to address the issues involved in scaling up what are at present laboratory research scale methods. The proposed study will examine these scale-up issues and establish the fundamentals of filamentous phage processing for applications in stringently regulated industries. For filamentous phages to be brought rapidly into the mainstream of large-scale use, it is imperative that we understand how to prepare the many different variants that there will be. The application fits within the Bioscience Engineering cross-committee priority area as it will apply engineering principles to biological materials. The studies proposed will allow the translation of phage biology discoveries into new pharmaceutical products.

Summary

The extensive knowledge of phage (also known as bacteriophages and bacterial viruses) genetics and physiology acquired in the past 50 years makes them an attractive option for development of products for pharmaceutical, diagnostic and nanotechnological applications. Modified phages are showing promise in the battle to defeat infectious and genetic diseases. For example, it has been shown that HIV epitopes displayed on a filamentous phage can elicit T-cell and B-cell responses offering a novel approach for vaccine design for a disease that affects approximately 6 million world-wide. Modified phages can be synthesised in high titres in E. coli and in principle processed by techniques readily applicable to considerable scale-up. Until a recently resurgence of interest in phages as anti-microbial agents there has been little research concern with large-scale processing since a few early studies 30 years ago. For this reason modern biochemical engineering and molecular biology concepts have yet to be brought together to address the issues involved. The proposed study will examine these. As the crisis in antibiotic drug resistance by microorganisms continues to develop it is also possible that phages will have an antibiotic role. Though this is not the primary focus of this research, the biochemical engineering studies proposed will bear on to this related field.

Committee	Closed Committee - Engineering & Biological Systems (EBS)
Research Topics	Industrial Biotechnology, Microbiology, Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search